Acura Pharmaceuticals
ACUR
ACUR was delisted on the 22nd of February, 2017.
2 hedge funds and large institutions have $215K invested in Acura Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
42% less capital invested
Capital invested by funds: $372K → $215K (-$157K)
Top Buyers
Top Sellers
ACUR Hedge Fund Activity: Q4 2018 in Review
2 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Acura Pharmaceuticals (ACUR) for Q4 2018, worth a combined $215K — down 42% from $372K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ACUR positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
- 2 institutional investors held Acura Pharmaceuticals (ACUR) as of Q4 2018, up from 1 in Q3 2018.
- Funds reported $215K of Acura Pharmaceuticals stock for Q4 2018, down 42% quarter-over-quarter.
- 1 fund opened new Acura Pharmaceuticals positions in Q4 2018 and 0 closed out, a net change of +1 holder.
Based on aggregated 13F filings for Q4 2018.